...
首页> 外文期刊>Clinical Endocrinology >Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease
【24h】

Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease

机译:短期补充碘化物对格雷夫斯病引起的甲状腺毒症的抗甲状腺药物治疗的益处

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective Combined treatment with anti-thyroid drugs (ATDs) and potassium iodide (KI) has been used only for severe thyrotoxicosis or as a pretreatment before urgent thyroidectomy in patients with Graves' disease. We compared methimazole (MMI) treatment with MMI + KI treatment in terms of rapid normalization of thyroid hormones during the early phase and examined the later induction of disease remission.Design and patients A total of 134 untreated patients with Graves' disease were randomly assigned to one of four regimens: Group 1, MMI 30 mg; Group 2, MMI 30 mg + KI; Group 3, MMI 15 mg and Group 4, MMI 15 mg + KI. For easy handling, KI tablets were used instead of saturated solution of KI. KI was discontinued when patients showed normal free thyroxine (FT4) levels but MMI was continued with a tapering dosage until remission. Remission rate was examined during a 4- to 5-year observation. Measurements Serum FT4, FT3 and TSH were measured by chemiluminescent immunoassays. TSH receptor antibody (TRAb) was assayed with TRAb-ELISA. Goitre size was estimated by ultra-sonography.Results After 2 weeks of treatment, normal FT4 was observed in 29% of patients in Group 1 and 59% (P < 0-05) of patients in Group 2. Furthermore, normal FT4 after 2 weeks of treatment was observed in 27% of patients in Group 3 and 54% (P < 0-05) of patients in Group 4. Similarly, FT3 normalized more rapidly in Groups 2 and 4 than in Groups 1 and 3. None of the patients showed an increase in thyroid hormones or aggravation of disease during combined treatment with MMI and KI. The remission rates in Groups 1, 2, 3 and 4 were 34%, 44%, 33% and 51%, respectively, and were higher in the groups receiving combined therapy but differences among four groups did not reach significance. Conclusions Combined treatment with MMI and KI improved the short-term control of Graves' hyperthyroidism and was not associated with worsening hyperthyroidism or induction of thiona-mide resistance.
机译:目的将抗甲状腺药物(ATDs)和碘化钾(KI)联合治疗仅用于严重的甲状腺毒症或在格雷夫斯病患者进行紧急甲状腺切除术之前进行的预处理。我们比较了甲巯咪唑(MMI)治疗与MMI + KI治疗在早期甲状腺激素快速正常化方面的差异,并检查了疾病缓解的后期诱发因素。设计和患者随机将134名未经治疗的Graves病患者分配到四种治疗方案之一:第1组,MMI 30 mg;第2组,MMI 30毫克+ KI;第3组,MMI 15毫克,第4组,MMI 15毫克+ KI。为了易于处理,使用KI片剂代替KI的饱和溶液。当患者显示正常的游离甲状腺素(FT4)水平时,KI停药,但继续以逐渐减少的剂量服用MMI,直至缓解。在4至5年的观察期间检查缓解率。测量通过化学发光免疫测定法测量血清FT4,FT3和TSH。用TRAb-ELISA法测定TSH受体抗体(TRAb)。结果经治疗2周后,第1组的患者中FT4正常,而第2组的患者中FT4正常(2 <59)(P <0-05)。在第3组的27%的患者和第4组的54%(P <0-05)的患者中观察到了3周的治疗。类似地,第2和第4组的FT3正常化比第1和3组更快。 MMI和KI联合治疗期间,患者显示甲状腺激素增加或疾病加重。第1、2、3和4组的缓解率分别为34%,44%,33%和51%,在接受联合治疗的组中较高,但四组之间的差异没有显着性。结论MMI和KI联合治疗可改善Graves甲状腺功能亢进症的短期控制,与甲状腺功能亢进症恶化或对硫代亚胺耐药性的诱导无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号